Pharmaceutical News

RSS

Members of priority groups to receive H1N1 vaccines from Department of Health

The Department of Health reminded Pennsylvanians they can begin making appointments today to be vaccinated against the H1N1 flu virus.

1 Dec 2009

CCII capsules offer safe and effective treatment for rheumatoid arthritis

Chicken collagen can provide relief from rheumatoid arthritis (RA) symptoms. A randomised, controlled trial, published in BioMed Central's open access journal Arthritis Research & Therapy, has found that Chicken type II collagen (CCII), a protein extracted from the cartilage of chicken breast, is a safe and effective treatment for RA.

1 Dec 2009

Phase 1 study of preventive HIV vaccine testing a novel delivery mechanism completed

A Phase 1 study of a preventive HIV vaccine testing a novel delivery mechanism known as electroporation – the use of electrical pulses to increase the immune responses elicited by DNA vaccines – was recently completed in New York City.

1 Dec 2009

Research shows many factors can impact people's decisions on getting vaccinated

Just because a vaccine is available doesn't mean people will choose to be inoculated, according to new UofT research published amid widespread public confusion around the merit of H1N1 flu shots.

1 Dec 2009

PanGenex plans to expand its retail product line with the addition of spirulla

PanGenex Corporation, a global nutraceutical and dietary supplement manufacturer and marketer, announced today that it has solidified plans to expand its retail product line with the addition of spirulla.

1 Dec 2009

Neurotoxic heavy metal can slow the progression of Lou Gehrig's disease

New discoveries have been made about how an elevated level of lead, which is a neurotoxic heavy metal, can slow the progression of amyotrophic lateral sclerosis, or Lou Gehrig's disease - findings that could point the way to a new type of therapy.

1 Dec 2009

GLUMETZA patent infringement lawsuit against Lupin

Depomed, Inc. today announced that it has filed a lawsuit in the United States District Court for the Northern District of California against Lupin Limited and its wholly-owned subsidiary, Lupin Pharmaceuticals, Inc., for infringement of the patents listed in the Orange Book for GLUMETZA® (metformin hydrochloride extended release tablets).

30 Nov 2009

Pharmacists could play important role in reform

Pharmacists may play an important role in the health care system by filling in health care gaps and advising patients, according to a series of articles in The Los Angeles Times, which reports on one clinical pharmacist Steven Chen and the "Patient Safety and Clinical Pharmacy Services Collaborative, a national project under the Health Resources and Services Administration that is working to integrate clinical pharmacy services into the care of patients with chronic diseases.

30 Nov 2009

BioMarin Pharmaceutical receives FDA orphan drug designation for 3,4-DAP

BioMarin Pharmaceutical Inc. announced today that the Food and Drug Administration (FDA) has granted orphan drug designation for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has previously received orphan drug designation in the E.U.

30 Nov 2009

Xencor licenses its XmAb and Xtend technology platforms to Centocor Research & Development

Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology platforms to Centocor Research & Development, Inc. for the optimization of Centocor’s antibody drug candidates.

30 Nov 2009

Bavarian Nordic to file a NDS for IMVAMUNE with Health Canada

Bavarian Nordic A/S announced today that the company expects to file a New Drug Submission (NDS) for its third-generation smallpox vaccine, IMVAMUNE(R) with the Canadian Authorities, Health Canada in 2010. If successful, this would be the first marketing approval of IMVAMUNE(R).

30 Nov 2009

Allos Therapeutics granted U.S. patent for FOLOTYN

Allos Therapeutics, Inc. today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN™ (pralatrexate injection) for the treatment of T-cell lymphoma. U.S. Patent No. 7,622,470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025.

30 Nov 2009

Eli Lilly's Cymbalta receives FDA approval

The U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, announced Eli Lilly and Company (NYSE: LLY).

30 Nov 2009

Cell Therapeutics' platinum-based anti-tumor compounds demonstrate stronger anti-tumor potency

Cell Therapeutics, Inc. (CTI) announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines.

30 Nov 2009

CCAC congratulates the Ontario government for expanding access to Avastin

The Colorectal Cancer Association of Canada (CCAC) applauds the Ontario Ministry of Health and Long-Term Care's decision today to provide expanded access of Avastin (bevacizumab) to patients with metastatic colorectal cancer.

30 Nov 2009

PanGenex expects release of television program on Calci-CLEAR dietary supplement

PanGenex Corporation announced today that it anticipates the release of its long form television program, demonstrating the benefits of Calci-CLEAR™, its patent pending dietary supplement that addresses soft tissue calcification, pursuant to its partnership with Incredible Discoveries® in early 2010.

28 Nov 2009

EMEA determines MAA for omacetaxine mepesuccinate for treatment of CML patients

ChemGenex Pharmaceuticals Limited announced today that the European Medicines Agency ("EMEA") has determined that the Marketing Authorization Application ("MAA") for omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation is valid.

28 Nov 2009

Cromoz's new drug delivery system to reduce amount of drugs used in cancer treatment

Cromoz Inc., located in Research Triangle Park, will initiate water-soluble carbon nanotube-based cancer drug delivery system in Hyderabad, India. The water-soluble carbon nanotubes, which have functional groups on the walls that allows for conjugation with cancer drugs, was developed in partnership with the Indian Institute of Kanpur (ITT). The conjugated carbon nanotubes serves as a drug delivery vehicle with the ability to target the cancer site which has the potential to increase the drug efficacy.

28 Nov 2009

Agriflu approved to prevent diseases caused by influenza virus subtypes A and B

The U.S. Food and Drug Administration today approved Agriflu for people ages 18 years and older to prevent disease caused by influenza virus subtypes A and B.

27 Nov 2009

Rights Issue to be carried out by keeping the authorization by the Annual General Meeting, resolves Tripep

The Board of Directors of Tripep AB (publhas on the 27th of November 2009, based on the authorization by the Annual General Meeting resolved to carry out a rights issue.

27 Nov 2009